BioHarvest Sciences (BHST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Anthony Vendetti from Maxim Group reiterated a Buy rating on the stock and has a $12.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anthony Vendetti has given his Buy rating due to a combination of factors that highlight BioHarvest Sciences’ strong performance and growth potential. The company reported first-quarter 2025 revenue that exceeded both consensus and guidance, demonstrating robust growth, particularly in its VINIA sales, which increased significantly year-over-year. This growth is supported by a solid direct-to-consumer subscriber base and successful sales on platforms like Amazon.
Additionally, BioHarvest Sciences has made notable progress in its Contract Development and Manufacturing Organization (CDMO) business, advancing a significant project with a Nasdaq-listed pharmaceutical partner to Phase 2. This advancement is crucial as it indicates the technical viability of their CDMO operations. The company is also making strategic investments in expanding its production capacity, which positions it well for future growth. Despite some delays in new product launches, the company’s innovative technology platform and strong market opportunities justify a premium valuation, supporting the Buy rating.
According to TipRanks, Vendetti is an analyst with an average return of -27.9% and a 22.06% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Dermata Therapeutics, Nephros, and SeaStar Medical Holding.
In another report released yesterday, Craig-Hallum also reiterated a Buy rating on the stock with a $15.00 price target.